Evidence map›Paper›PMID 36621198›Full record

ArticleDrug and alcohol dependence2023

Cost-effectiveness of office-based buprenorphine treatment for opioid use disorder.

Gary Qian, Isabelle Rao, Keith Humphreys, Douglas K Owens, Margaret L Brandeau

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug and alcohol dependence, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Observational
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Gary QianDepartment of Management Science and Engineering, Stanford University, Stanford, CA, USA. Electronic address: gqia189@stanford.edu.
Isabelle RaoDepartment of Management Science and Engineering, Stanford University, Stanford, CA, USA.
Keith HumphreysCenter for Innovation to Implementation, US Department of Veterans Affairs, VA Palo Alto Health Care System, Palo Alto, CA, USA; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA, USA.
Douglas K OwensDepartment of Health Policy, School of Medicine, and Stanford Health Policy, Freeman-Spogli Institute for International Studies, Stanford University, Stanford, CA, USA.
Margaret L BrandeauDepartment of Management Science and Engineering, Stanford University, Stanford, CA, USA.

Funding

Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR01DA015612 · NIDA · STANFORD UNIVERSITY · PI OWENS, DOUGLAS K · 2002 to 2017
$9.4M
Making Better Decisions: Policy Modeling for AIDS and Drug AbuseR37DA015612 · NIDA · STANFORD UNIVERSITY · PI DOUGLAS K OWENS · 2019 to 2026
$6.3M
Cost Effectiveness of Interventions to Reduce Morbidity from Opioid DependencyI01HX002457 · VA · VETERANS ADMIN PALO ALTO HEALTH CARE SYS · PI OWENS, DOUGLAS K · 2018 to 2023
–
HSRD VA I01 HX002457NIDA NIH HHS R01 DA015612NIDA NIH HHS R37 DA015612
6 · The paper itself

Abstract

aimTo assess the effectiveness and cost-effectiveness of office-based buprenorphine treatment (OBBT) in the U.S. DESIGN SETTING AND

participantsWe performed a model-based analysis of buprenorphine treatment provided in a primary care setting for the U.S. population with OUD.

interventionBuprenorphine treatment provided in a primary care setting. MEASUREMENTS: Fatal and nonfatal overdoses and deaths over five years, discounted lifetime quality-adjusted life years (QALYs), costs.

findingsFor a cohort of 100,000 untreated individuals who enter OBBT, approximately 9350 overdoses would be averted over five years; of these, approximately 900 would have been fatal. OBBT compared to no treatment would yield 1.07 incremental lifetime QALYs per person at an incremental cost of $17,000 per QALY gained when using a healthcare perspective. If OBBT is half as effective and twice as expensive as assumed in the base case, the incremental cost when using a healthcare perspective is $25,500 per QALY gained. Using a limited societal perspective that additionally includes patient costs and criminal justice costs, OBBT is cost-saving compared to no treatment even under pessimistic assumptions about efficacy and cost.

conclusionsExpansion of OBBT would be highly cost-effective compared to no treatment when considered from a healthcare perspective, and cost-saving when reduced criminal justice costs are included. Given the continuing opioid crisis in the U.S., expansion of this care option should be a high priority.

Indexed as

BuprenorphineOpioid-Related DisordersCost-Benefit AnalysisHumansQuality-Adjusted Life YearsBuprenorphineCost-effectiveness analysisDynamic compartmental modelOffice-based buprenorphine treatmentOpioid use disorderSimulation modelingTreatment access

Identifiers

PMID36621198
PMCPMC9852082

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.